Search / 81 results found

from
to
  • Updated

SOMERVILLE, Mass., Oct. 21, 2021 /PRNewswire/ -- Greentown Labs, the largest climatetech startup incubator in North America, Saint-Gobain, a multinational manufacturer and distributor of high-performance materials, and the Massachusetts Clean Energy Center (MassCEC), an economic development agency dedicated to accelerating the clean energy sector across the state, have selected five startups for the Healthy Buildings Challenge that are developing technologies that advance building sustainability and wellbeing for building occupants. The latest iteration of the Greentown Launch corporate partnerships accelerator, the Healthy Buildings Challenge is focused on solutions that optimize for the health of people and the climate and aims to foster collaboration between Saint-Gobain and the participating startups, with support from MassCEC.

  • Updated

CAMBRIDGE, Mass. and MINNEAPOLIS, Oct. 21, 2021 /PRNewswire/ -- CIBO, the science-based technology company that supports growers and enterprises on their journey to regenerative agriculture, today announced it has closed $30 million in series-C financing.

  • Updated

LAUSANNE, Switzerland and BOSTON, Oct. 19, 2021 /PRNewswire/ -- Debiopharm (www.debiopharm.com), a Swiss-based global biopharmaceutical company announced today having been awarded the third phase funding to advance the development of its antibiotic program, Debio 1453, by the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), a Boston-based non-profit accelerating antibacterial research. This extended financing will support the ongoing development of a novel antibiotic for the treatment of Neisseria gonorrhoeae infections, including those caused by multi-resistant strains. This extension of over $1 million will allow the completion of preliminary toxicology studies needed to determine the doses for pivotal toxicology research as well as optimize the production steps of the development candidate. This is a step towards the development of an affordable, quality product for human use and eventual clinical research. This funding succeeds the previous rounds over the last 4 years supporting earlier research, totaling up to $4 million since 2017.

  • Updated

LAUSANNE, Switzerland and BOSTON, Oct. 19, 2021 /CNW/ -- Debiopharm (www.debiopharm.com), a Swiss-based global biopharmaceutical company announced today having been awarded the third phase funding to advance the development of its antibiotic program, Debio 1453, by the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), a Boston-based non-profit accelerating antibacterial research. This extended financing will support the ongoing development of a novel antibiotic for the treatment of Neisseria gonorrhoeae infections, including those caused by multi-resistant strains. This extension of over $1 million will allow the completion of preliminary toxicology studies needed to determine the doses for pivotal toxicology research as well as optimize the production steps of the development candidate. This is a step towards the development of an affordable, quality product for human use and eventual clinical research. This funding succeeds the previous rounds over the last 4 years supporting earlier research, totaling up to $4 million since 2017.

  • Updated

LAUSANNE, Switzerland and BOSTON, Oct. 19, 2021 /PRNewswire/ -- Debiopharm (www.debiopharm.com), a Swiss-based global biopharmaceutical company announced today having been awarded the third phase funding to advance the development of its antibiotic program, Debio 1453, by the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), a Boston-based non-profit accelerating antibacterial research. This extended financing will support the ongoing development of a novel antibiotic for the treatment of Neisseria gonorrhoeae infections, including those caused by multi-resistant strains. This extension of over $1 million will allow the completion of preliminary toxicology studies needed to determine the doses for pivotal toxicology research as well as optimize the production steps of the development candidate. This is a step towards the development of an affordable, quality product for human use and eventual clinical research. This funding succeeds the previous rounds over the last 4 years supporting earlier research, totaling up to $4 million since 2017.